Region-level spatial gene expression beats bulk RNA signatures for ranking anticancer compounds in triple-negative breast cancer
- Bulk RNA signatures average away intratumoral differences, so the authors score compounds against localized spatial expression signatures instead, focusing on heterogeneous triple-negative breast cancer.
- They compared bulk and spatial signatures on a set of about 1,300 diverse compounds, evaluating how well each ranked known anticancer drugs.
- Spatial signatures ranked known anticancer drugs better than bulk ones and also flagged unclassified and non-oncology compounds as candidates; evidence is computational, with no experimental validation described.
💡 Points Based on the abstract
Ranking known anticancer drugs higher is a retrospective enrichment test in one cancer type, and it doesn't show the spatial signature will find new ones. There's no wet-lab follow-up, and nothing on leakage or baselines. The non-oncology hits are the interesting part; I'll reserve judgment until a few are actually tested.